It's not a secret that every investor will make bad investments, from time to time. But serious investors should think long and hard about avoiding extreme losses. It must have been painful to be a ...
HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...
Werewolf Therapeutics, Inc. (HOWL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HOWL's 50-day simple moving average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback